Disease · MONDO_0005383

panic disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. panic disorder. Diseases, record MONDO_0005383. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005383

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: panic disorder; Open Targets
Open Targets ID: MONDO_0005383; Open Targets
Other names: panic anxiety syndrome, panic attack, panic attacks, panic disorder syndrome, panic syndrome; Open Targets
Disease Ontology: DOID:594; Disease Ontology
MeSH: D016584; MeSH
NCI Thesaurus: C34890; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 39 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs39

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALPRAZOLAM	CHEMBL661	Small molecule	Approval	DailyMed and FDA	76	7	7	Drugs and targets
VENLAFAXINE HYDROCHLORIDE	CHEMBL1201066	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
CLONAZEPAM	CHEMBL452	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
PAROXETINE HYDROCHLORIDE	CHEMBL6067650	Small molecule	Approval	DailyMed	40	0	0	Drugs and targets
PAROXETINE MESYLATE	CHEMBL1200609	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
BROMAZEPAM	CHEMBL277062	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PAROXETINE	CHEMBL490	Small molecule	Phase 3	ClinicalTrials.gov	9	9	8	Drugs and targets
CYCLOSERINE	CHEMBL771	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
RISPERIDONE	CHEMBL85	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
VENLAFAXINE	CHEMBL637	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 39

See all 39 drugs

Targets60

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A4	Sodium-dependent serotonin transporter	17	Serotonin transporter inhibitor	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
GABRA1	GABA A receptor alpha-1/beta-1/gamma-2	6	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2554	Drugs and targets
GABRB1	GABA A receptor alpha-1/beta-1/gamma-2	6	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2560	Drugs and targets
GABRG2	GABA A receptor alpha-1/beta-1/gamma-2	6	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2566	Drugs and targets
GABRA2	GABA-A receptor; anion channel	5	GABA receptor alpha-2 subunit positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2561	Drugs and targets

1 to 10 of 60

See all 60 targets

Trials36

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00605917	Special Investigation Of J Zoloft For Panic Disorder Patients		997	2012-09-21	Panic Disorder	SERTRALINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00790868	Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder	Phase 2	180	2018-03-07	Panic Disorder	CYCLOSERINE	Its record names the disease	ClinicalTrials.gov
NCT02218736	Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a	Phase 2	163	2019-01-08	ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)	ATICAPRANT	Its record names the disease	ClinicalTrials.gov
NCT00803400	Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment	Phase 4	150	2008-12-05	Panic Disorder	ALPRAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT01944423	Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine	Early phase 1	53	2021-05-19	Nicotine Addiction, Panic Attack	(+/-)NICOTINE, CYCLOSERINE, NICOTINE	Its record names the disease	ClinicalTrials.gov
NCT00477451	Staccato Alprazolam in Panic Attack	Phase 2	49	2017-06-16	Treatment of Induced Panic Attack	ALPRAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT00118417	Therapies for Treatment-Resistant Panic Disorder Symptoms	Phase 2/3	46	2009-07-28	Panic Disorder	CLONAZEPAM, SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT00725725	Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)	Phase 2	46	2016-12-30	Panic Disorder	ORG-25935	Its record names the disease	ClinicalTrials.gov
NCT00746239	Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety	Not applicable	11	2015-10-15	Panic Disorder, Insomnia	ESCITALOPRAM, RAMELTEON	Its record names the disease	ClinicalTrials.gov
NCT02476136	Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis		8,800		Anxiety Disorders, Panic Disorder, Obsessive-compulsive Disorder, Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder	DULOXETINE, FLUOXETINE, PAROXETINE, VENLAFAXINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 36

See all 36 trials

Comparisons in its trials16

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
With Non-pharmaceutical Therapies vs Without Non-pharmaceutical Therapies: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Non-Pharmaceutical Therapies	65 of 405	45 of 503	908	NCT00605917	Trial comparisons
With Complications vs Without Complications: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications	47 of 305	63 of 603	908	NCT00605917	Trial comparisons
With Past Medical History of Other Illness vs Without Past Medical History of Other Illness: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness	25 of 103	85 of 805	908	NCT00605917	Trial comparisons
With Concomitant Drug vs Without Concomitant Drug: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug	94 of 665	16 of 243	908	NCT00605917	Trial comparisons
With Concomitant Drug vs Without Concomitrant: Factors Considered to Affect the Efficacy of Sertraline: Concomitant Drug	565 of 649	216 of 232	881	NCT00605917	Trial comparisons
With Complications vs Without Complications: Factors Considered to Affect the Efficacy of Sertraline: Complication	246 of 292	535 of 589	881	NCT00605917	Trial comparisons
With History of Treatment vs Without History of Treatment: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: History of Treatment Prior to Administration of Sertraline	33 of 200	73 of 679	879	NCT00605917	Trial comparisons
With Family History vs Without Family History: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Family History of Psychiatric Disorder	11 of 52	78 of 697	749	NCT00605917	Trial comparisons
D-cycloserine vs Placebo: deaths from any cause	0 of 88	0 of 92	180	NCT00790868	Trial comparisons
D-cycloserine vs Placebo: serious adverse events	1 of 88	1 of 92	180	NCT00790868	Trial comparisons

1 to 10 of 16

See all 16 comparisons in its trials

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27315514	RESULT	1	PubMed
19042026	RESULT	1	PubMed
38160885	DERIVED	1	PubMed
37935477	DERIVED	1	PubMed
32229324	DERIVED	1	PubMed
32004998	DERIVED	1	PubMed
29659102	DERIVED	1	PubMed
27777612	DERIVED	1	PubMed
26663632	DERIVED	1	PubMed
23808960	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005383

GET https://conductscience.org/api/diseases/v1/MONDO_0005383/drugs?page=2

API reference For AI assistants